홈 › 폐암 › 사우스다코타 › Sioux Falls
SD Sioux Falls의 폐암 임상 시험
폐암 관련 연구 14개가 Sioux Falls 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
피험자 모집 중3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
피험자 모집 중3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
피험자 모집 중3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
피험자 모집 중3상
- Avera Cancer Institute, Sioux Falls
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
피험자 모집 중3상
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
피험자 모집 중2상
- Sanford Cancer Center ( Site 0038), Sioux Falls
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
피험자 모집 중3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
피험자 모집 중2상
- Sanford Cancer Center, Sioux Falls
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
피험자 모집 중2상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2상
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Avera Cancer Sequencing and Analytics Protocol (ASAP)
피험자 모집 중관찰 연구
- Avera Cancer Institute, Sioux Falls
다른 도시의 폐암 시험
- Houston, TX연구 78개
- Boston, MA연구 62개
- New York City, NY연구 60개
- Los Angeles, CA연구 45개
- Arlington, VA연구 41개
- Washington, DC연구 41개
- Chicago, IL연구 41개
- Baltimore, MD연구 40개
- Nashville, TN연구 40개
- St. Louis, MO연구 39개
- Columbus, OH연구 37개
- Philadelphia, PA연구 36개
Sioux Falls의 다른 연구
- 비소세포폐암연구 19개
- 유방암연구 18개
- 난소암연구 16개
- 암 (전체)연구 13개
- 자궁내막암연구 11개
- 전이성 암연구 10개
- 대장직장암연구 9개
- 두경부 편평세포암연구 9개
- 심부전연구 7개
- 결장암연구 7개
- 삼중음성 유방암연구 7개
- 전립선암연구 7개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.